BioRestorative Therapies, Inc. (BRTX)
↓ Download CSV- Sector Services
- Incorporated NV
- Fiscal year ends Dec 31
In fiscal 2025, BioRestorative Therapies, Inc. reported revenue of $359.7K, down 10.3% from the prior year. The company ran a net loss, with a net margin of -3959.4% and a gross margin of 93.4%.
Key ratios (FY2025)
93.4%
Gross margin
-4350.1%
Operating margin
-3959.4%
Net margin
-3992.2%
Return on equity
-10.3%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $359.7K | $401.0K | $145.8K | $119.8K | $46.0K | $77.0K | $130.0K | $111.0K | $81.0K | — |
| Cost of Revenue | $23.8K | $28.1K | — | — | — | — | — | — | — | — |
| Gross Profit | $335.9K | $372.9K | $145.8K | — | — | — | — | — | $81.0K | $36.3K |
| Operating Income | -$15.65M | -$11.56M | -$15.22M | -$18.97M | -$26.31M | -$2.75M | -$8.43M | -$7.65M | -$8.37M | -$7.79M |
| Net Income | -$14.24M | -$8.98M | -$10.42M | -$13.22M | -$44.30M | -$11.27M | -$14.65M | -$12.52M | -$9.44M | -$8.64M |
| EPS (Diluted) | $-1.58 | $-1.16 | $-2.47 | $-3.65 | $-37.30 | — | — | — | — | — |
| Total Assets | $4.08M | $12.28M | $12.61M | $16.43M | $22.45M | $4.35M | $1.47M | $1.19M | $1.76M | $1.58M |
| Total Liabilities | — | $3.75M | $2.61M | $6.14M | $856.5K | $5.68M | $14.24M | $9.83M | $8.60M | $6.58M |
| Shareholders' Equity | $356.7K | $8.53M | $10.00M | $10.29M | $10.78M | -$1.33M | -$12.78M | -$8.64M | -$6.84M | -$5.00M |
| Cash & Equivalents | $1.51M | $547.9K | $884.4K | $1.71M | $21.03M | — | — | — | — | — |
| Operating Cash Flow | -$10.79M | -$8.23M | -$6.43M | -$5.91M | -$3.33M | -$1.96M | -$6.92M | -$5.10M | -$3.85M | — |
| Capital Expenditures | $116.1K | $106.2K | $171.0K | $265.2K | $30.7K | — | $35.6K | $12.9K | $3.6K | $188.8K |
| Shares Outstanding | 8.88M | 6.92M | 4.71M | 3.68M | 3.52M | 715.5K | 77.85M | 11.73M | 6.11M | 4.70M |